Novartis AG Common Stock (NY:NVS)

FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults ↗

November 25, 2025

Novartis wins FDA approval for Itvisma, a one-time gene therapy offering broader SMA treatment with sustained motor function improvements.

Via Benzinga

Novartis Stock Rises Premarket After FDA Approves First Gene Therapy For Teens And Adults With Muscle-Weakening Disorder ↗

November 25, 2025

FDA cleared Itvisma as the first gene-replacement therapy available to people 2 and older with the rare muscle-weakening condition.

Novartis (NVS) appears undervalued with a low P/E ratio, strong profitability, and solid financial health, making it a compelling stock for value investors.

NOVARTIS AG-SPONSORED ADR (NYSE:NVS): A Comprehensive Value Investment Analysis ↗

November 24, 2025

Via Chartmill

European Stocks Soar as Strong Earnings Quell 'AI Bubble' Fears

November 20, 2025

European equity markets have experienced a significant resurgence around November 20, 2025, with major indices climbing as robust company results, particularly from the technology sector, have...

Via MarketMinute

Novartis Stock Softens Premarket Even As It Raises 2030 Outlook, Sales Guidance For Two Key Cancer Drugs ↗

November 20, 2025

Novartis raises long-term sales targets, boosts outlook for key medicines and outlines a pipeline strategy driving growth through 2030.

Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts ↗

November 20, 2025

Via Benzinga

Big Pharma Layoff Wave Extends Into Next Year: UNH, Merck, BMS, Novartis File New WARN Notices ↗

November 20, 2025

AI breakthroughs in pharma are pushing Eli Lilly and healthcare stocks higher—and may soon reshape how we fight cancer.

Topics Workforce

Is the Market Bullish or Bearish on Novartis AG? ↗

November 18, 2025

Via Benzinga

Is AI The Key To Beating Cancer? Why Pharma Stocks Are Soaring ↗

November 17, 2025

Via Benzinga

Topics Artificial Intelligence

Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Strong Case for Dividend Investors ↗

November 17, 2025

Novartis (NVS) offers a strong 3.31% dividend yield with a history of reliable payouts and growth, backed by excellent profitability and financial health.

Via Chartmill

Novartis Opens New Manufacturing Facility In California In Bid To Increase US Presence ↗

November 10, 2025

Trump Unveils $200 Billion Trade Deal With Switzerland And Liechtenstein To Cull $38.5 Billion US Goods Deficit By 2028 ↗

November 15, 2025

President Donald Trump announced a framework for a trade deal with Switzerland and Liechtenstein on Friday.

Via Benzinga

Topics Government

AI Revolutionizes Drug Shelf-Life: Optimized Stability Models Promise Safer, More Effective Medicines

November 14, 2025

The pharmaceutical industry is on the cusp of a profound transformation, driven by the integration of data science and Artificial Intelligence (AI) into drug formulation stability models. This...

Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025

Topics Artificial Intelligence Economy Product Recall

November 14, 2025

The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

AI Revolutionizes Cardiovascular Clinical Trials: A Leap Towards Cheaper, Faster Drug Development

November 13, 2025

San Francisco, CA – November 13, 2025 – Artificial Intelligence (AI) has achieved a pivotal breakthrough in the medical field, successfully adjudicating clinical events in cardiovascular trials. This...

Novartis' Investigational Medicine Shows Potent Activity Against Drug-Resistant Malaria Strains ↗

Topics Artificial Intelligence

November 13, 2025

Novartis' GanLum met key Phase 3 goals, showing strong efficacy and safety in malaria patients, including against resistant parasite strains.

Via Benzinga

Eledon Pharmaceuticals Stock Plunges Following $50 Million Public Offering

November 12, 2025

Irvine, CA – November 12, 2025 – Eledon Pharmaceuticals (NASDAQ: ELDN) witnessed a significant decline in its stock value today, plummeting by 17.8% in premarket trading. This sharp drop comes on the...

Via MarketMinute

Topics Initial Public Offering Intellectual Property Regulatory Compliance

AI’s Next Frontier: Key Stocks to Watch Amidst Market Shifts and Technological Leaps

November 10, 2025

The artificial intelligence (AI) sector is currently navigating a period of unprecedented dynamism, characterized by explosive technological advancements, massive capital inflows, and a palpable...

Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design...

Topics Artificial Intelligence

AI Achieves Atomic Precision in Antibody Design: A New Era for Drug Discovery Dawns

November 05, 2025

The company hopes to "solve a 20-year riddle" in cancer treatment. The journey has sent the biotech stock flying as much as 534%.

Topics Artificial Intelligence Intellectual Property

Celcuity Eyeing Cancer Treatment Riddle. Stock Flys 534% This Year. ↗

November 05, 2025

Via Investor's Business Daily

AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential

November 04, 2025

The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central...

Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades ↗

Topics Artificial Intelligence

November 03, 2025

Terns Pharmaceuticals shares rise after TERN-701 shows a 75% response rate in the CML trial, and William Blair upgrades the stock to Outperform.

Via Benzinga

iShares Core MSCI EAFE ETF (IEFA) Focuses on Developed Markets While Vanguard FTSE All-World ex-US ETF (VEU) Looks Globally ↗

November 03, 2025

iShares Core MSCI EAFE ETF (IEFA) Focuses on Developed Markets While Vanguard FTSE All-World ex-US ETF (VEU) Looks Globally

Trump offers help to cancer-stricken Dilbert creator Scott Adams after he appeals for assistance on social media. Adams seeks access to Pluvicto treatment for metastatic prostate cancer.

Topics ETFs

Trump Offers Help To 'Dilbert' Creator's Cancer Fight ↗

November 03, 2025

Via Benzinga

Topics Government

The Vanguard FTSE Developed Markets ETF (VEA) Offers Broader Diversification Than the SPDR Portfolio Developed World ex-US ETF (SPDW) ↗

November 02, 2025

The Vanguard FTSE Developed Markets ETF (VEA) Offers Broader Diversification Than the SPDR Portfolio Developed World ex-US ETF (SPDW)

Vanguard VEA ETF Boasts Broader Portfolio Than State Street's SPDR SPDW

Topics ETFs

Vanguard VEA ETF Boasts Broader Portfolio Than State Street's SPDR SPDW ↗

November 02, 2025

The biopharmaceutical industry is undergoing an immediate and profound transformation, as Artificial Intelligence (AI) rapidly compresses timelines, drastically reduces costs, and significantly...

Topics ETFs

AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio

November 01, 2025

The pharmaceutical sector stands at the precipice of a profound transformation, driven by the relentless march of artificial intelligence (AI) and other advanced technologies. As highlighted by...

Topics Animal Testing Artificial Intelligence Economy

The AI Imperative: Why Rapid Upskilling is Non-Negotiable for Pharma’s Future

October 31, 2025

San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of...

Topics Artificial Intelligence Economy

AI Revolutionizes Pharma: Smarter Excipients for Safer, More Potent Drugs

October 31, 2025